Mersana Therapeutics | ARS:年度报告
Mersana Therapeutics | DEF 14A:股东委托书决议
Mersana Therapeutics | DEFA14A:其他
Mersana Therapeutics | 4:持股变动声明-董事 Alleva Lawrence M
Mersana Therapeutics | 8-K:重大事件
Mersana Therapeutics | 424B5:募资说明书
Mersana Therapeutics | POS AM:修改注册声明表
Mersana Therapeutics | 10-K:年度报表
Mersana Therapeutics | POSASR:注册声明修正稿
Mersana Therapeutics | 8-K:Mersana Therapeutics提供最新业务并公布2023年第四季度和全年财务业绩
Mersana Therapeutics | 4/A:持股变动声明(修正)-高管 Mandelia Ashish
Mersana Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Venrock Healthcare Capital Partners III, L.P.(9.4%),VHCP Co-Investment Holdings III, LLC(9.4%)等
Mersana Therapeutics | SC 13G:超过5%持股股东披露文件-SilverArc Capital Management, LLC(5.3%),Devesh Gandhi(5.3%)
Mersana Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-OrbiMed Capital LLC(0.0%),OrbiMed Advisors LLC(0.0%)
Mersana Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Avoro Capital Advisors LLC(0%),Behzad Aghazadeh(0%)
Mersana Therapeutics | SC 13G:超过5%持股股东披露文件-Balyasny Asset Management L.P.(8.04%),BAM GP LLC(8.04%)等
Mersana Therapeutics | SC 13G:超过5%持股股东披露文件-The Vanguard Group(5.17%)
Mersana Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-BlackRock, Inc.(6.5%)
Mersana Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-STATE STREET CORPORATION(1.93%)
Mersana Therapeutics | 4:持股变动声明-董事 Protopapas Anna
暂无数据